Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation.

The presence and benefit of a radiation therapy-associated immune reaction is of great interest as the overall interest in cancer immunotherapy expands. The pathological assessment of irradiated tumors rarely demonstrates consistent immune or inflammatory response. More recent information, primarily associated with the "abscopal effect", suggests a subtle radiation-based systemic immune response may be more common and have more therapeutic potential than previously believed. However, to be of consistent value, the immune stimulatory potential of radiation therapy (RT) will clearly need to be supported by combination with other immunotherapy efforts. In this study, using a spontaneous canine oral melanoma model, we have assessed the efficacy and tumor immunopathology of two nanotechnology-based immune adjuvants combined with RT. The immune adjuvants were administered intratumorally, in an approach termed "in situ vaccination", that puts immunostimulatory reagents into a recognized tumor and utilizes the endogenous antigens in the tumor as the antigens in the antigen/adjuvant combination that constitutes a vaccine. The radiation treatment consisted of a local 6 × 6 Gy tumor regimen given over a 12 day period. The immune adjuvants were a plant-based virus-like nanoparticle (VLP) and a 110 nm diameter magnetic iron oxide nanoparticle (mNPH) that was activated with an alternating magnetic field (AMF) to produce moderate heat (43 °C/60 min). The RT was used alone or combined with one or both adjuvants. The VLP (4 × 200 μg) and mNPH (2 × 7.5 mg/gram tumor) were delivered intratumorally respectively during the RT regimen. All patients received a diagnostic biopsy and CT-based 3-D radiation treatment plan prior to initiating therapy. Patients were assessed clinically 14-21 days post-treatment, monthly for 3 months following treatment, and bimonthly, thereafter. Immunohistopathologic assessment of the tumors was performed before and 14-21 days following treatment. Results suggest that addition of VLPs and/or mNPH to a hypofractionated radiation regimen increases the immune cell infiltration in the tumor, extends the tumor control interval, and has important systemic therapeutic potential.

[1]  N. Steinmetz,et al.  Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response. , 2017, Nano letters.

[2]  C. London,et al.  Dogs as a Model for Cancer. , 2016, Annual review of animal biosciences.

[3]  Y. Choi,et al.  Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? , 2016, PloS one.

[4]  P. Lizotte,et al.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.

[5]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[6]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[7]  S. Fiering,et al.  Local tumour hyperthermia as immunotherapy for metastatic cancer , 2014, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[8]  P Jack Hoopes,et al.  Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[9]  P. Newell,et al.  Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice , 2014, Radiation research.

[10]  C. Barker,et al.  Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. , 2014, International journal of radiation oncology, biology, physics.

[11]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[12]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[13]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[14]  S. Demaria,et al.  Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..

[15]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[16]  J. Wolchok,et al.  Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy , 2011, Cancer journal.

[17]  C. N. Coleman,et al.  Fractionated Radiation Therapy Can Induce a Molecular Profile for Therapeutic Targeting , 2010, Radiation research.

[18]  I. Baker,et al.  MAGNETIC NANOPARTICLE HYPERTHERMIA IN CANCER TREATMENT. , 2010, Nano LIFE.

[19]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[20]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[21]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[22]  P. Bergman Canine oral melanoma. , 2007, Clinical techniques in small animal practice.

[23]  James B. Mitchell,et al.  Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.

[24]  P Wust,et al.  Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[25]  Roland Felix,et al.  The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma , 2006, Journal of Neuro-Oncology.

[26]  R. Packer,et al.  Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). , 2003, Journal of the American Veterinary Medical Association.

[27]  R. Dodge,et al.  A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. , 2003, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[28]  W. Dewey,et al.  Thermal dose determination in cancer therapy. , 1984, International journal of radiation oncology, biology, physics.

[29]  L. Peters,et al.  Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. , 1979, Journal of the National Cancer Institute.

[30]  Sungjune Kim,et al.  The immune mechanisms of abscopal effect in radiation therapy. , 2016, Current problems in cancer.

[31]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[32]  S. Siva,et al.  Abscopal effects of radiation therapy: a clinical review for the radiobiologist. , 2015, Cancer letters.

[33]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[34]  I. Baker,et al.  Surface Engineering of Core/Shell Iron/Iron Oxide Nanoparticles from Microemulsions for Hyperthermia. , 2010, Materials science & engineering. C, Materials for biological applications.

[35]  Peter Wust,et al.  Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme , 2006, Journal of Neuro-Oncology.